← Back to Screener
Savara Inc. (SVRA)
Price$5.61
Favorite Metrics
Price vs S&P 500 (26W)57.63%
Price vs S&P 500 (4W)2.29%
Market Capitalization$1.15B
All Metrics
Book Value / Share (Quarterly)$0.99
P/TBV (Annual)6.41x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.49
Price vs S&P 500 (YTD)-10.90%
Net Profit Margin (TTM)-4253.85%
EPS (TTM)$-0.53
10-Day Avg Trading Volume1.27M
EPS Excl Extra (TTM)$-0.53
EPS (Annual)$-0.48
ROI (Annual)-48.47%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-11537.00%
Cash / Share (Quarterly)$1.15
ROA (Last FY)-45.10%
EBITD / Share (TTM)$-0.55
ROE (5Y Avg)-47.43%
Operating Margin (TTM)-4150.00%
Cash Flow / Share (Annual)$-0.49
P/B Ratio5.65x
P/B Ratio (Quarterly)6.04x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)4403.29x
Net Interest Coverage (TTM)-345.82x
ROA (TTM)-63.60%
EPS Incl Extra (Annual)$-0.48
Current Ratio (Annual)11.85x
Quick Ratio (Quarterly)11.66x
3-Month Avg Trading Volume1.97M
52-Week Price Return86.38%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.94
P/S Ratio (Annual)4415.88x
Asset Turnover (Annual)0.00x
52-Week High$7.00
Operating Margin (5Y Avg)-11595.18%
EPS Excl Extra (Annual)$-0.48
CapEx CAGR (5Y)-63.27%
Tangible BV CAGR (5Y)29.74%
26-Week Price Return64.52%
Quick Ratio (Annual)11.68x
13-Week Price Return-4.59%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)11.85x
Enterprise Value$1,144.856
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-3.49%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-19084.62%
Cash / Share (Annual)$1.15
3-Month Return Std Dev52.57%
Net Income / Employee (TTM)$-2
ROE (Last FY)-55.99%
Net Interest Coverage (Annual)-18.37x
EPS Basic Excl Extra (Annual)$-0.48
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$-0.53
ROI (TTM)-69.42%
P/S Ratio (TTM)4415.88x
Pretax Margin (5Y Avg)-11907.77%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.94
Price vs S&P 500 (52W)51.75%
Year-to-Date Return-6.97%
5-Day Price Return-7.58%
EPS Normalized (Annual)$-0.48
ROA (5Y Avg)-35.67%
Net Profit Margin (Annual)-19084.62%
Month-to-Date Return2.75%
Cash Flow / Share (TTM)$-0.31
EBITD / Share (Annual)$-0.48
Operating Margin (Annual)-18961.54%
LT Debt / Equity (Annual)0.15x
ROI (5Y Avg)-38.10%
LT Debt / Equity (Quarterly)0.15x
EPS Basic Excl Extra (TTM)$-0.53
P/TBV (Quarterly)6.41x
P/B Ratio (Annual)6.04x
Pretax Margin (TTM)-4253.85%
Book Value / Share (Annual)$0.99
Price vs S&P 500 (13W)-6.97%
Beta0.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-84.01%
52-Week Low$1.89
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SVRASavara Inc. | 4415.88x | — | — | — | $5.61 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Savara Inc. is a specialty pharmaceutical company developing treatments for rare respiratory diseases. Its lead program, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).